Unknown

Dataset Information

0

Immunohistochemistry and alternative FISH testing in breast cancer with HER2 equivocal amplification.


ABSTRACT: PURPOSE:While HER2 testing is well established in directing appropriate treatment for breast cancer, a small percentage of cases show equivocal results by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). Alternative probes may be used in equivocal cases. We present a single community-based institution's experience in further evaluating these cases. PATIENTS AND METHODS:Between 2014 and 2016, 4255 samples were submitted for HER2 amplification testing by alternative probes, TP53, RAI1, and RARA. Of the patients tested by FISH, 505/3908 (12.9%) also had IHC data. RESULTS:Most (73.9%) FISH equivocal cases remained equivocal after IHC testing. However, 50.5% of equivocal cases were classified as HER2 amplified by alternative probes. Most cases were positive by more than one probe: 78% of positive cases by RAI1 and 73.9% by TP53. There was a significant difference between IHC and FISH alternative testing (p?

SUBMITTER: Agersborg S 

PROVIDER: S-EPMC5999182 | biostudies-literature | 2018 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

Immunohistochemistry and alternative FISH testing in breast cancer with HER2 equivocal amplification.

Agersborg Sally S   Mixon Christopher C   Nguyen Thanh T   Aithal Sramila S   Sudarsanam Sucha S   Blocker Forrest F   Weiss Lawrence L   Gasparini Robert R   Jiang Shiping S   Chen Wayne W   Hess Gregory G   Albitar Maher M  

Breast cancer research and treatment 20180322 2


<h4>Purpose</h4>While HER2 testing is well established in directing appropriate treatment for breast cancer, a small percentage of cases show equivocal results by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). Alternative probes may be used in equivocal cases. We present a single community-based institution's experience in further evaluating these cases.<h4>Patients and methods</h4>Between 2014 and 2016, 4255 samples were submitted for HER2 amplification testing by alt  ...[more]

Similar Datasets

| S-EPMC5533703 | biostudies-literature
| S-EPMC6439848 | biostudies-literature
2017-01-01 | GSE86305 | GEO
| S-EPMC8742337 | biostudies-literature
| S-EPMC7660495 | biostudies-literature
| S-EPMC3570596 | biostudies-literature
| S-EPMC6715641 | biostudies-literature
| S-EPMC5074347 | biostudies-literature
| S-EPMC6110371 | biostudies-literature
| S-EPMC4746572 | biostudies-literature